Comparison · NCT02968849-e8fe64d6
Vaccine vs Placebo: Number of Participants With Viral Sequences at HIV-1 Diagnosis
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Vaccine vs Placebo: Number of Participants With Viral Sequences at HIV-1 Diagnosis. Trial comparisons, record NCT02968849-e8fe64d6. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02968849-e8fe64d6
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.975 | 0.93 | 0.992 | wilson | |
| Risk in group 2 | 0.983 | 0.94 | 0.995 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0075 | -0.0544 | 0.0385 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.992 | 0.956 | 1.03 | log | |
| Odds ratio, group 1 over group 2 | 0.69 | 0.113 | 4.2 | log | |
| Number needed to treat, for one fewer participant with the outcome on Vaccine than on Placebo | 133 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Vaccine | ALVAC-HIV at months 0, 1, 3, 6, 12, 18, and bivalent subtype C gp120/MF9 at months 3, 6, 12, 18 | 119 | 122 | OG000 |
| Group 2 | Placebo | Placebo for ALVAC-HIV at months 0, 1, 3, 6, 12, 18, and placebo for bivalent subtype C gp120/MF9 at months 3, 6, 12, 18 | 115 | 117 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Viral Sequences at HIV-1 Diagnosis
- Description
Number of participants in the female mITT cohort with viral sequences were reported. Viral sequencing was conducted on the earliest available plasma specimens with positive HIV-1 RNA PCR tests from study participants who are diagnosed with HIV-1 infection.
- Time frame
- Measured through 24 months after first vaccination
- Population
- The female mITT cohort was the group of participants used in sieve analysis.
Source ClinicalTrials.gov
Trial
- Title
- Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa
- NCT number
- NCT02968849
- Phases
- PHASE2, PHASE3
- Conditions
- HIV Infections
- Interventions
- ALVAC-HIV (vCP2438), Bivalent Subtype C gp120/MF59, Placebo
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Results first posted
- 2023-02-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02968849?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02968849-e8fe64d6